Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Given Consensus Rating of “Moderate Buy” by Analysts

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) has been given a consensus rating of “Moderate Buy” by the twelve analysts that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $44.00.

A number of brokerages have recently issued reports on DMRA. Royal Bank Of Canada began coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Friday, April 24th. They issued an “outperform” rating and a $40.00 price target on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Damora Therapeutics, Inc. Common Stock in a report on Thursday, June 18th. HC Wainwright reaffirmed a “buy” rating and set a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Jefferies Financial Group assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, July 27th. They issued a “buy” rating and a $50.00 target price on the stock. Finally, TD Cowen started coverage on shares of Damora Therapeutics, Inc. Common Stock in a report on Monday, June 8th. They issued a “buy” rating for the company.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of institutional investors and hedge funds have recently made changes to their positions in DMRA. Janus Henderson Group PLC purchased a new position in Damora Therapeutics, Inc. Common Stock during the fourth quarter worth about $40,000. Geode Capital Management LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $266,000. Virtu Financial LLC purchased a new stake in shares of Damora Therapeutics, Inc. Common Stock in the 3rd quarter valued at about $49,000. Sigma Planning Corp bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $334,000. Finally, Two Sigma Investments LP bought a new stake in shares of Damora Therapeutics, Inc. Common Stock during the 3rd quarter valued at about $76,000. Hedge funds and other institutional investors own 14.20% of the company’s stock.

Damora Therapeutics, Inc. Common Stock Stock Performance

NASDAQ:DMRA opened at $28.99 on Friday. The business’s fifty day moving average is $26.00 and its 200 day moving average is $26.06. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -5.20 and a beta of 1.46. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.45 and a 52-week high of $38.33.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) last issued its earnings results on Wednesday, May 13th. The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.23). Equities analysts predict that Damora Therapeutics, Inc. Common Stock will post -1.92 EPS for the current fiscal year.

About Damora Therapeutics, Inc. Common Stock

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.